BOSTON SCIENTIFIC CORP (BSX) Earnings History

5 quarters held2/5 transcripts analyzed2/25 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$5.4B+7.5%$907.0M$0.61Jul 29, 2026
LATESTEarnings filing (8-K)10-QFiled Jul 29, 2026, 6:33 AM ET
Earnings call · Jul 29, 2026
Q2 FY26YoY6M FY26
Revenue$5.4B1+7.5%–
Net income$907.0M+13.8%$2.2B
Op income$1.2B+43.8%$2.3B
EPS (dil.)$0.61––
EPS (basic)$0.62+14.8%–
Gross margin70.7%+3.1pp
Op margin21.6%+5.5pp
Net margin16.7%+0.9pp
  1. [1] “Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational 1 and organ” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

other
6—8
other
5—7
eps_diluted
$0.82—$0.84
other
1—1

fy_full

other
6—7
other
5—6
eps_diluted
$3.28—$3.32

q_next

other
3—5
eps_diluted
$0.80—$0.82
Q1 2026$5.2B+11.6%$1.3B$0.90Apr 22, 2026
Earnings filing (8-K)10-QFiled Apr 22, 2026, 6:34 AM ET
Earnings call · Apr 22, 2026transcriptView originalprepared remarksQ&A
Q1 FY26YoY
Revenue$5.2B+11.6%
Net income$1.3B+99.0%
Op income$1.1B+19.5%
EPS (dil.)$0.90+100.0%
EPS (basic)$0.90+95.7%
Gross margin69.5%+0.6pp
Op margin21.2%+1.4pp
Net margin25.8%+11.3pp
Q4 2025$5.3B+15.9%$672.0M$0.45Feb 4, 2026
Earnings filing (8-K)10-KFiled Feb 4, 2026, 6:33 AM ET
Q4 FY25YoYFY25
Revenue$5.3B1+15.9%$20.1B
Net income$672.0M+18.7%$2.9B
Op income$825.0M+22.2%$3.6B
EPS (dil.)$0.45–$1.94
EPS (basic)$0.45+18.4%$1.96
Gross margin69.6%+1.7pp
Op margin15.6%+0.8pp
Net margin12.7%+0.3pp
  1. [1] “generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis” view source
Q3 2025$5.1B+20.3%$755.0M$0.51Oct 22, 2025
Earnings filing (8-K)10-QFiled Oct 22, 2025, 6:32 AM ET
Earnings call · Oct 22, 2025transcriptprepared remarksQ&A
Q3 FY25YoY9M FY25
Revenue$5.1B+20.3%$14.8B
Net income$755.0M+61.0%$2.2B
Op income$1.0B+43.0%$2.8B
EPS (dil.)$0.51+59.4%$1.49
EPS (basic)$0.51+59.4%$1.50
Gross margin69.9%+1.1pp
Op margin20.7%+3.3pp
Net margin14.9%+3.8pp
Q2 2025$5.1B+22.8%$797.0M$0.53Jul 23, 2025
Earnings filing (8-K)10-QFiled Jul 23, 2025, 6:32 AM ET
Q2 FY25YoY
Revenue$5.1B+22.8%
Net income$797.0M+146.0%
Op income$819.0M+57.5%
EPS (dil.)$0.53+140.9%
EPS (basic)$0.54+145.5%
Gross margin67.7%-1.5pp
Op margin16.2%+3.6pp
Net margin15.8%+7.9pp

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

67 filings indexed · 67,087 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-08-03–39106
8-K2026-07-29Q2 202660
8-K2026-05-18–30
8-K2026-05-18–30
8-K2026-05-05–10
10-Q2026-05-01–3898
8-K2026-04-22Q1 202660
8-K2026-03-30–40
8-K2026-02-26–10
8-K2026-02-23–40

Showing the latest 10 of 67 — the full set is in the API.

Related Research

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

Medical Device ROIC Rankings: Why Abbott's 26% Beats Medtronic's 7% (The Gross Margin Paradox)